Table 1.
Current CAR-NK therapy clinical trials in hematological tumors.
| Row | Status | Disease | Construct/Combination | NK Cell sources | Phase | Nar patients | Country | NCT number |
|---|---|---|---|---|---|---|---|---|
| 1 | Recruiting | Acute Myeloid Leukemia | NKG2D CAR | Cord blood | Phase 1 | 9 | China | NCT05247957 |
| 2 | Recruiting | B-cell Non Hodgkin Lymphoma | CD19 CAR | Haploidentical donor | Phase 1 | 25 | China | NCT04887012 |
| 3 | Recruiting | Acute Myeloid Leukemia | CD33/CLL1 CAR | Unknown | Early Phase 1 | 18 | China | NCT05215015 |
| 4 | Not yet recruiting | Non Hodgkin Lymphoma | CD19 CAR | Unknown | Early Phase 1 | 9 | China | NCT04639739 |
| 5 | Recruiting | Acute Myeloid Leukemia | CD33 CAR | Unknown | Phase 1 | 27 | China | NCT05008575 |
| 6 | Unknown | Refractory B-Cell Lymphoma | CD22 CAR | Unknown | Early Phase 1 | 9 | Unknown | NCT03692767 |
| 7 | Unknown | Refractory B-Cell Lymphoma | CD19 CAR | Unknown | Early Phase 1 | 9 | Unknown | NCT03690310 |
| 8 | Recruiting | Refractory Multiple Myeloma | BCMA CAR | Cord blood | Early Phase 1 | 27 | China | NCT05008536 |
| 9 | Recruiting | Multiple Myeloma | BCMA CAR | NK-92 cell line | Phase 1/2 | 20 | China | NCT03940833 |
| 10 | Unknown | Refractory B-cell Lymphoma | CD19/CD22 CAR | Unknown | Early Phase 1 | 10 | Unknown | NCT03824964 |
| 11 | Recruiting | Relapsed/Refractory Acute Myelodysplastic Syndromes | NKX101 (NKG2D CAR/mbIL-15) | Haploidentical donor (PB) | Phase 1 | 90 | USA | NCT04623944 |
| 12 | Recruiting | B-cell Leukemias Waldenstrom Macroglobulinemia B-cell Lymphomas | NKX019 (CD19 CAR/mbIL-15) | Donor (PB) | Phase 1 | 60 | USA Australia | NCT05020678 |
| 13 | Unknown | Acute Myeloid Leukemia Acute nonlymphocytic leukemia |
CD33 CAR | NK-92 cell line | Phase 1/2 | 10 | China | NCT02944162 |
| 14 | Recruiting | Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non Hodgkin’s Lymphoma |
CD19 CAR | Cord blood | Phase 1 | 27 | China | NCT04796675 |
| 15 | Unknown | B-cell Leukemias B-cell Lymphomas |
CD19 CAR | NK-92 cell line | Phase 1/2 | 10 | China | NCT02892695 |
| 16 | Withdrawn | B-cell Lymphomas | CAR CD19/iCasp9/IL 15 + Rituximab | Cord blood | Phase 1/2 | 0 | USA | NCT03579927 |
| 17 | Active not recruiting | B-cell Leukemias B-cell Lymphomas |
iCasp9/CAR CD 19/IL15 + AP1903 | Cord blood | Phase 1/2 | 36 | USA | NCT03056339 |
| 18 | Recruiting | Multiple Myeloma | FT576(BCMA CAR) + Daratumumab | iPSCs | Phase 1 | 168 | USA | NCT05182073 |
| 19 | Not yet recruiting | B-cell Lymphoma Myelodysplastic Syndromes Acute Myeloid Leukemia |
CARCD70/IL 15 | Cord blood | Phase 1/2 | 94 | USA | NCT05092451 |
| 20 | Not yet recruiting | CD19-Positive B-cell Malignancies | CNTY-101 (CAR CD19/EGFR/IL15) +IL-2 | iPSCs | Phase 1 | 75 | Unknown | NCT05336409 |
| 21 | Not yet recruiting | Hematological Malignancies | CAR CD5/IL 15 | Cord blood | Phase 1/2 | 48 | USA | NCT05110742 |
| 22 | Unknown | CD7-Positive Leukemia or Lymphoma | CD7 CAR | NK-92 cell line | Phase 1/2 | 10 | China | NCT02742727 |
| 23 | Recruiting | B-cell Lymphoma | FT596 (CD19 CAR) | iPSCs | Phase 1 | 50 | USA | NCT04555811 |
| 24 | Recruiting | B-cell Lymphoma Chronic Lymphocytic Leukemia |
FT596 (CD19 CAR) + Rituximab | iPSCs | Phase 1 | 285 | USA | NCT04245722 |
| 25 | Completed | Acute Lymphoblastic Leukemia | CD19 CAR | Haploidentical donor (PB) | Phase 1 | 14 | USA | NCT00995137 |
| 26 | Withdrawn | Diffuse Large B Cell Lymphoma | CD19 CAR | Modified NK-92 (haNK) | Phase 1 | 0 | USA | NCT04052061 |
| 27 | Suspended | B-cell Acute Lymphoblastic Leukemia | CD19 CAR + IL-2 | Haploidentical donor (PB) | Phase 1 | 20 | Singapore | NCT01974479 |
| 28 | Unknown | B-cell Leukemias B-cell Lymphomas |
CD19 CAR | NK-92 cell line | Phase 1/2 | 10 | China | NCT02892695 |
| 29 | Recruiting | B-cell Non Hodgkin Lymphoma | CAR CD19/IL15 | Cord blood | Phase 2 | 242 | USA | NCT05020015 |
| 30 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) B-cell Lymphoma | QN-019a (CAR CD19) +/- Rituximab | Allogenic | Phase 1 | 24 | China | NCT05379647 |
| 31 | Recruiting | Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | CD19 CAR | Unknown | Phase 1 | 15 | China | NCT05410041 |